TABLE 3.
Effect of AT1R blockade on cardiovascular sensitivity to hypoxic apnea before (Pre) and after (Post) 8 h of nocturnal hypoxia.
| Drug | Pre | Post | Drug | Condition | Interaction | |
| ΔSBP/ΔSpO2 | Losartan | 3.1 ± 0.6 | 3.6 ± 0.7 | P = 0.22 | P = 0.90 | P = 0.28 |
| (mmHg/%desaturation) | Placebo | 3.1 ± 0.6 | 2.4 ± 0.6 | |||
| ΔDBP/ΔSpO2 | Losartan | 2.3 ± 0.4 | 2.9 ± 0.5 | P = 0.60 | P = 0.30 | P = 0.23 |
| (mmHg/%desaturation) | Placebo | 2.5 ± 0.4 | 2.2 ± 0.5 | |||
| ΔMAP/ΔSpO2 | Losartan | 2.5 ± 0.5 | 3.1 ± 0.7 | P = 0.43 | P = 0.98 | P = 0.24 |
| (mmHg/%desaturation) | Placebo | 2.7 ± 0.5 | 2.1 ± 0.4 | |||
| ΔHR/ΔSpO2 | Losartan | 1.6 ± 0.3 | 2.5 ± 0.4 | P = 0.42 | P = 0.06 | P = 0.14 |
| (bpm/%desaturation) | Placebo | 1.8 ± 0.3 | 1.9 ± 0.3 |
All values are mean ± SEM. ΔSpO2, % of oxyhemoglobin desaturation;ΔSBP, change in systolic blood pressure;ΔDBP, change in diastolic blood pressure; ΔMAP, change in mean arterial pressure;ΔHR, change in heart rate.